Want to see IN:JUBLPHARMA full AI Analyst Report?
Top Page
Jubilant Pharmova Limited
(JUBLPHARMA)
Select Model
Select Model
Rating:51Neutral
Price Target:
₹1,030.00
▲(7.07% Upside)
Action:Reiterated
Date:08/25/26
The score is primarily held back by inconsistent profitability and especially unreliable free cash flow, despite steady revenue growth and manageable (but rising) leverage. Technicals are bearish with price below key moving averages and negative MACD, while valuation is expensive (high P/E and low yield), limiting upside unless margins and cash generation improve.
Positive Factors
Diversified life-sciences platform
The company serves customers across pharmaceutical development, manufacturing, and commercialization, with several complementary revenue streams. This breadth can diversify demand, support customer relationships across the lifecycle, and provide multiple avenues for durable growth.
Negative Factors
Volatile profitability and margins
Large swings in profitability make earnings less predictable and weaken confidence in the durability of recent gains. The FY2026 gross-margin decline may constrain operating leverage, reduce reinvestment capacity, and leave results more sensitive to mix, pricing, or costs.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified life-sciences platform
The company serves customers across pharmaceutical development, manufacturing, and commercialization, with several complementary revenue streams. This breadth can diversify demand, support customer relationships across the lifecycle, and provide multiple avenues for durable growth.
Read all positive factors
Jubilant Pharmova Limited (JUBLPHARMA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹163.28B
Dividend Yield0.49%
Average Volume (3M)24.66K
Price to Earnings (P/E)46.1
Beta (1Y)0.97
Revenue Growth16.27%
EPS Growth-23.50%
CountryIN
Employees6,386
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)22.24
Shares Outstanding159,281,140
10 Day Avg. Volume27,271
30 Day Avg. Volume24,659
Financial Highlights & Ratios
PEG Ratio-0.62
Price to Book (P/B)1.82
Price to Sales (P/S)1.56
P/FCF Ratio-29.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)38.98
Revenue Forecast (FY)₹93.55B
Jubilant Pharmova Limited Business Overview & Revenue Model
Company Description
Jubilant Pharmova Limited functions as a comprehensive pharmaceutical enterprise with a global footprint, structured into three primary divisions: Pharmaceuticals; Contract Research & Development Services; and Proprietary Novel Drugs. The Pharmace...
How the Company Makes Money
Jubilant Pharmova makes money primarily by selling products and services across multiple life-sciences businesses. A major revenue stream comes from contract development and manufacturing (CDMO) and related services, where the company earns fees a...
Jubilant Pharmova Limited Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
58
Neutral
Cash Flow
45
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 86.08B | 82.80B | 72.34B | 67.03B | 62.82B | 61.30B |
| Gross Profit | 25.01B | 24.94B | 46.99B | 43.52B | 42.00B | 46.42B |
| EBITDA | 12.13B | 12.66B | 10.48B | 7.93B | 6.46B | 10.66B |
| Net Income | 3.52B | 3.98B | 8.39B | 771.00M | -610.00M | 4.14B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 155.23B | 127.56B | 115.48B | 111.57B | 99.91B |
| Cash, Cash Equivalents and Short-Term Investments | 12.67B | 12.68B | 10.89B | 9.56B | 10.15B | 9.86B |
| Total Debt | 0.00 | 36.15B | 27.31B | 36.64B | 36.77B | 31.92B |
| Total Liabilities | -70.96B | 84.27B | 65.18B | 61.27B | 57.65B | 46.74B |
| Stockholders Equity | 70.96B | 70.93B | 62.55B | 54.34B | 53.99B | 53.19B |
Cash Flow | ||||||
| Free Cash Flow | -3.71B | -4.36B | -435.00M | 736.00M | -1.54B | 2.38B |
| Operating Cash Flow | 3.69B | 10.13B | 10.72B | 9.71B | 6.61B | 8.38B |
| Investing Cash Flow | -6.31B | -12.85B | 4.88B | -6.08B | -5.44B | -3.80B |
| Financing Cash Flow | -1.84B | 3.33B | -14.53B | -4.33B | -1.57B | -325.99M |
Jubilant Pharmova Limited Technical Analysis
Positive
962.00
Price Trends
942.58
Positive
955.74
Positive
955.69
Positive
Market Momentum
21.96
Negative
74.82
Negative
96.84
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:JUBLPHARMA, the sentiment is Positive. The current price of 962 is above the 20-day moving average (MA) of 917.42, above the 50-day MA of 942.58, and above the 200-day MA of 955.69, indicating a bullish trend. The MACD of 21.96 indicates Negative momentum. The RSI at 74.82 is Negative, neither overbought nor oversold. The STOCH value of 96.84 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:JUBLPHARMA.
Jubilant Pharmova Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | ₹170.06B | 28.23 | ― | 0.36% | 7.93% | 21.51% | |
67 Neutral | ₹109.33B | 17.78 | ― | 0.42% | 7.28% | 68.82% | |
66 Neutral | ₹301.97B | 60.66 | ― | 0.14% | 78.33% | 182.61% | |
64 Neutral | ₹225.41B | 33.60 | ― | 0.19% | 24.83% | 36.88% | |
58 Neutral | ₹354.41B | 86.62 | ― | 1.27% | 18.37% | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | ₹163.28B | 46.10 | ― | 0.49% | 16.27% | -23.50% |
* General Sector Average
IN:JUBLPHARMA
Jubilant Pharmova Limited
1,025.10
-90.23
-8.09%
IN:ALIVUS
Glenmark Life Sciences Limited
1,385.15
457.32
49.29%
IN:GRANULES
Granules India Limited
909.65
377.41
70.91%
IN:NEULANDLAB
Neuland Laboratories Ltd.
23,536.20
7,872.60
50.26%
IN:STAR
Strides Pharma Science Ltd
1,186.10
302.78
34.28%
IN:WOCKPHARMA
Wockhardt Limited
2,181.15
669.55
44.29%
Jubilant Pharmova Limited Corporate Events
Jubilant Pharmova Opens Special Window for Physical Share Transfers and KYC Update
Aug 29, 2026
Jubilant Pharmova has notified stock exchanges that it has published newspaper advertisements informing shareholders about a special window for re-lodgement of transfer requests for physical shares. The company is also urging investors to update t...
Jubilant Pharmova Wins USFDA Nod for New Spokane Fill-and-Finish Line
Aug 22, 2026
Jubilant Pharmova Limited announced that the U.S. Food and Drug Administration has approved commercial batch manufacturing of the first product on Line 3, a new isolator-based fill-and-finish line at subsidiary Jubilant HollisterStier’s cont...
Jubilant Pharmova Publishes AGM, E-Voting and Dividend Notice
Aug 2, 2026
Jubilant Pharmova Limited operates in the pharmaceutical and life sciences sector, offering a range of healthcare and related products and services. The company is listed on BSE and the National Stock Exchange of India under the symbol JUBLPHARMA,...
Jubilant Pharmova Updates Shareholders on AGM, Annual Report Access
Aug 1, 2026
Jubilant Pharmova has informed exchanges that it has dispatched physical letters to shareholders whose email IDs are not registered, directing them to web links where the company’s FY 2025-26 annual report, TDS communication, and notice of i...
Jubilant Pharmova Sets Final Dividend and Details TDS Rules for Shareholders
Aug 1, 2026
Jubilant Pharmova has informed shareholders that its board has recommended a final dividend of ₹5 per equity share for the financial year ended March 31, 2026, payable to investors on record as of July 24, 2026, subject to approval at the up...
Jubilant Pharmova Wins USFDA Tentative Nod for Pantoprazole Oral Suspension
Jun 25, 2026
Jubilant Pharmova has announced that its subsidiary Jubilant Generics has received tentative approval from the USFDA for Pantoprazole Sodium Delayed Release Oral Suspension, 40 mg per packet, produced at its Roorkee solid dosage facility. The appr...
Jubilant Pharmova’s Spokane Plant Clears USFDA Inspection Without Sterility Issues
Jun 19, 2026
Jubilant Pharmova Limited announced that the U.S. Food and Drug Administration has completed an inspection of its contract manufacturing subsidiary Jubilant HollisterStier’s facility in Spokane, Washington. The inspection resulted in eight o...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.